Hasil Pencarian  ::  Simpan CSV :: Kembali

"This recent results in cancer research volume contains the majority of the invited expert contributions from the First St. Gallen EORTC Gastrointestinal Cancer Conference, held on 22-24 March 2012 in St. Gallen, Switzerland. Written by some of the world?s leading experts in the field, the volume constitutes a comprehensive update on recent developments in the imaging, molecular biology, pathology, and multidisciplinary management of early cancer of the gastrointestinal tract. The latest recommendations regarding diagnosis and treatment are provided, and areas of consensus and controversy, identified. While the principal focus is on esophageal and gastric cancer, advances in the treatment of colorectal and pancreatic cancer are also discussed in some detail."

"This book consists of sixteen chapters, providing concise reviews and expert opinions on the recent progress of materia medica research in fourteen particular cancers from bench to bedside application. In addition, the book also includes a chapter with an overview of evidence-based materia medica for cancer chemoprevention, as well as a chapter discussing on the pharmacokinetics of anticancer materia medica. Gathering international opinion leaders’ views, this volume will contribute great to the cancer, academic, and clinical community by providing evidence-based information on the anticancer effects of materia medica for various cancers."

"Cancer is one of the leading killers in the world and the incidence is increasing, but most cancer patients and cancer survivors suffer much from the disease and its conventional treatments side effects. In the past, clinical data showed that some complementary and alternative medicine (CAM) possessed anticancer abilities, but some clinicians and scientists have queried about the scientific validity of CAM due to the lack of scientific evidence. There is great demand in the knowledge gap to explore the scientific and evidence-based knowledge of CAM in the anticancer field. With this aim, a book series is needed to structurally deliver the knowledge to readers. There have been a number of publications on materia medica for various cancers in recent years, the scientific and medical community are thrust for up-to-date information that are supported by concrete laboratory evidences or clinical trials. This volume is a specialised book presenting the experimental and clinical evidences of anticancer materia medica for various cancers. This book consists of sixteen chapters, providing concise reviews and expert opinions on the recent progress of materia medica research in fourteen particular cancers from bench to bedside application. In addition, the book also includes a chapter with an overview of evidence-based materia medica for cancer chemoprevention, as well as a chapter discussing on the pharmacokinetics of anticancer materia medica. Gathering international opinion leaders views, this volume will contribute great to the cancer, academic, and clinical community by providing evidence-based information on the anticancer effects of materia medica for various cancers. Readership Oncologists, cancer researchers, pharmacologists, pharmaceutical specialists, Chinese medicine practitioners, medical educators, postgraduates and advanced undergraduates in biomedical disciplines, cancer caregivers, cancer patients."

"In the last decade, there has been a remarkable explosion of knowledge in hematologic cancer from basic molecular biology and pathology to clinical therapy. This has led to many new advance and insights in the understanding of pathobiology of malignant hematology. New knowledge of disease molecular pathology, cytogenetic, epigenetic and genomic alterations have provided new strategies to attack and eradicate tumor cells at molecular level and significantly impacted our current therapeutics for hematological malignancies. The recent and ongoing rapid expansion of knowledge in this area has become extensive, dynamic and diffuse over the literature and research publications. This has led to the need to capture and compile the new and current information about hematologic cancer with special emphasis on translation from molecular pathobiology to targeted therapeutics. In this book experts from around the world share their thoughts and knowledge about the pathobiology of hematologic cancer, as well as their view on current treatment approaches and future development in these malignant hematologic diseases. "

"We report three rare cases of mucosal-associated lymphoid tissue (MALT) lymphoma. Two cases are of gastric MALT lymphoma and one is a case of transverse colon MALT lymphoma. The two cases of gastric MALT lymphoma were diagnosed by endoscopy which demonstrated an ulcer in the cardia and another in the corpus. The first case is in a 62-year-old male. The patients medical history revealed upper GI tract bleeding with melaena in 1993. At the time no diagnosis was made on endoscopy In August 2000, melaena recurred and endoscopy showed an ulcer in the cardio. Histology showed high-grade gastric MALT lymphoma. Based on Ann Arbor classification, the patient was classified as stage IE gastrointestinal lymphoma. H. pylori was negative. The patient received chemotherapy The second case is in a 53-year-old male. He suffered from gastric lymphoma for 3 years. He complained of annually recurring haematemesis before a definitive diagnosis was finally established. He suffered jiom stage IE low-grade well-differentiated lymphocytic MALT lymphoma. H. pylori was negative. Endoscopic procedure after H. pylori eradication showed ulcer regression though histology still showed low-grade MALT lymphoma and H. pylori as positive. The third case is in a 46-year-old male with a complaint of haematochezia. Colonoscopy showed intususception due to tumor in the transverse colon. Histologic examination showed chronic colitis and granulomatosa. lnvagination due to colon tumor was reported. Histologic examination of the biopsy specimen showed low-grade small cell lymphocyte-plasmocytoid lymphoma. "

"The gastrointestinal track provides one of the distinct systems where multiple malignancies, including adenocarcinoma of the pancreas, esophagus and colon are each associated with obesity. The focus on possible dietary contribution as well as the role of exercise in prevention and therapy is presented in both animal model and patient based studies. Special focus is provided also on the role of genetic mutations and inflammatory pathways as drivers of these obesity related gastrointestinal malignancies. "

"ABSTRAKPenelitian ini dilakukan untuk mengetahui kadar fecal calprotectin (FC) pada anak dengan BB normal, BB lebih termasuk obesitas akibat inflamasi dan disfungsi saluran cerna serta faktor risiko apa saja pada awal kehidupan yang dapat menyebabkan terjadinya obesitas usia pra sekolah. Penelitian ini merupakan studi kasus-kontrol, subyek penelitian terdiri dari 58 anak kelompok kasus (BB lebih atau obesitas) dan 58 anak kelompok kontrol (BB normal) yang dipasangkandengan jenis kelamin, usia, dan sekolah. Hasil penelitian didapatkan median IMT z-zcore 2,05 (-1,86?6,78) SD, rerata asupan energi total sebesar 1541,66 + 389,69 kkal dan asupan lemak 54,92 + 17,48 gram. Didapatkan hubungan bermakna asupan energi total dan lemak pada kelompok kasus dan kontrol (p=0,040 danp=0.022). Tidak ditemukan hubungan bermakna kadar FC antara kelompok kasusdan kontrol (p=0,454). Dilakukan analisis multivariat terhadap faktor risiko awalkehidupan dengan status gizi lebih lebih dan kadar FC diaatas normal, tidakdidapatkan hubungan. Namun setelah dihubungkan dengan faktor penggangu,didapatkan kecendrungan kenaikan nilai OR dan penurunan p-value. Hal inimenunjukkan bahwa ada hubungan antara kejadian obesitas dan peningkatankadar FC pada anak pra sekolah dengan faktor risiko awal kehidupan

---

ABSTRACTThis study was conducted to determine levels of fecal calprotectin (FC) inchildren that have normal weight, overweight (OW) including obesity due toinflammation and dysfunction of the gastrointestinal tract and any risk factors inearly life can lead to obesity preschool children. This study was a case-controlstudy, subjects consisted of 58 children in group cases (OW or obese) and 58controls group (normal weight) were matched by sex, age, and school. The resultsshowed a median BMI z-zcore 2.05 (-1,86-6,78) SD. Mean total energy intake andfat intake were 1541.66+389.69 kcal and 54.92+17.48 grams. We foundsignificant relationship between subject cases and control for total energy intakeand fat intake (p=0,040 and p=0.022). And no significant value of FC betweencase and control (p=0,454). Multivariate analysis of the early life risk factors withnutritional status and levels of FC, no significant. However, after adjusted with adisturbance factor, obtained trend increase the value of OR and decrease p-value.This suggests that there is a relationship between the incidence of obesity in preschoolchildren and increased value of FC with risk factors early in life"

"Malay medicine is one of complementary and alternative medicines in preventing and treating many diseases. However, scientific observation on Malay medicine in treating several non-infectious diseases, including obesity and cancer has not been fully documented and may be obsoleted. Thus, this review compiled several data on the potential of Malay medicine practice by consumption of Gelam honey and herb named Tinospora crispa in controlling obesity and treating cancer. In obesity study, findings revealed Gelam honey, and T. crispa significantly decreased body weight, total cholesterol, triglycerides and the glucose level compared to controls. Meanwhile, in several cancer studies, both Gelam honey and T. crispa were found inhibited colon, breast, liver and lung cancer cell growth. Although the results were at the early stage, the reported studies revealed the potential of Gelam honey and T. crispa, which are applied in Malay medicine to control obesity and treat cancers effectively in the future. The data is also useful to conserve both native natural products and to promote a significant application of Malay medicine until to date."